<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pediatricjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Архив педиатрии и детской хирургии</journal-title><trans-title-group xml:lang="en"><trans-title>Archives of Pediatrics and Pediatric Surgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2949-4664</issn><issn pub-type="epub">3033-6783</issn><publisher><publisher-name>НИКИ детства Минздрава Московской области</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.66825/2949-4664-apps-4-2-46-54</article-id><article-id custom-type="elpub" pub-id-type="custom">pediatricjournal-279</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕВРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROLOGY</subject></subj-group></article-categories><title-group><article-title>Когнитивное, коммуникативное, социально-эмоциональное и адаптивное развитие у детей с мерозин-дефицитной мышечной дистрофией</article-title><trans-title-group xml:lang="en"><trans-title>Cognitive, communicative, socio-emotional, and adaptive development in children with merosin-deficient muscular dystrophy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9828-9348</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Монахова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Monakhova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Монахова Анастасия Вячеславовна, врач-невролог детского психоневрологического отделения № 2, младший научный сотрудник отдела психоневрологии и эпилептологии</p><p>125412, г. Москва, Талдомская ул., д. 2</p></bio><bio xml:lang="en"><p>Anastasia V. Monakhova, Department of рsychoneurology and epileptology</p><p>2 Taldomskaya str., Moscow, 125412</p></bio><email xlink:type="simple">stasya@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2635-2752</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Влодавец</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vlodavets</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Влодавец Дмитрий Владимирович, доцент, к.м.н. руководитель Российского детского нервно-мышечного центра, ведущий научный сотрудник отдела психоневрологии и эпилептологии</p><p>125412, г. Москва, Талдомская ул., д. 2</p></bio><bio xml:lang="en"><p>Dmitry V. Vlodavets, PhD (Medicine), Associate Professor, Head of the Russian children’s neuromuscular center, leading researcher of the Department of psychoneurology and epileptology</p><p>2 Taldomskaya str., Moscow, 125412</p></bio><email xlink:type="simple">mityaus@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Обособленное структурное подразделение Научно-исследовательского клинического института педиатрии и детской хирургии имени академика Ю.Е. Вельтищева Российского национального исследовательского медицинского университета имени Н.И. Пирогова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Yu.E. Veltishchev Research Clinical Institute of Pediatrics and Pediatric Surgery, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>19</day><month>07</month><year>2026</year></pub-date><volume>4</volume><issue>2</issue><fpage>46</fpage><lpage>54</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Монахова А.В., Влодавец Д.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Монахова А.В., Влодавец Д.В.</copyright-holder><copyright-holder xml:lang="en">Monakhova A.V., Vlodavets D.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nikid.ru/jour/article/view/279">https://journal.nikid.ru/jour/article/view/279</self-uri><abstract><p>Мерозин-дефицитная мышечная дистрофия - это нервномышечное заболевание с гетерогенным фенотипом, в основе которого лежит дефицит белка экстрацеллюлярного матрикса ламинина-211. Мерозинопатия традиционно рассматривается преимущественно как заболевание скелетной мускулатуры, проявляющееся мышечной гипотонией, задержкой моторного развития, прогрессирующей мышечной слабостью, контрактурами, сколиозом, дыхательными и нутритивными осложнениями. Вместе с тем накопленные данные свидетельствуют о том, что при мерозин-дефицитной мышечной дистрофии патологический процесс не ограничивается мышечной тканью. Особое значение имеет вовлечение центральной нервной системы, что создает патогенетические предпосылки для нарушений психического развития. В настоящем исследовании с использованием опросника DР-3 проведена комплексная оценка двигательной, адаптивной, когнитивной, коммуникативной и социально-эмоциональной сфер у пациентов с врожденной и поясно-конечностной формами мерозин-дефицитной мышечной дистрофии. Наиболее выраженное снижение показателей отмечалось в двигательной и адаптивной сферах у пациентов с врожденной формой заболевания. Вместе с тем у части пациентов выявлялись нарушения когнитивной, коммуникативной и социально-эмоциональной сфер, тогда как у отдельных больных когнитивные показатели соответствовали среднему уровню или превышали его. Полученные данные подчеркивают неоднородность когнитивно-поведенческого профиля заболевания и необходимость индивидуальной комплексной оценки психического развития у пациентов с мерозинопатией.</p></abstract><trans-abstract xml:lang="en"><p>Merosin-deficient muscular dystrophy is a neuromuscular disorder with a heterogeneous phenotype caused by deficiency of the extracellular matrix protein laminin-211. Merosinopathy has traditionally been considered primarily a skeletal muscle disease, manifesting with muscular hypotonia, delayed motor development, progressive muscle weakness, contractures, scoliosis, respiratory and nutritional complications. However, accumulating evidence indicates that in merosin-deficient muscular dystrophy the pathological process is not limited to muscle tissue. Involvement of the central nervous system is of particular importance, as it creates pathogenetic prerequisites for impairments in mental development. In the present study, a comprehensive assessment of motor, adaptive, cognitive, communicative, and socioemotional domains was performed using the DP-3 questionnaire in patients with congenital and limbgirdle forms of merosin-deficient muscular dystrophy. The most pronounced decrease in scores was observed in the motor and adaptive domains in patients with the congenital form of the disease; at the same time, some patients demonstrated impairments in the cognitive, communicative, and socio-emotional domains, whereas in individual cases cognitive scores were within or above the average range. These findings highlight the heterogeneity of the cognitive-behavioral profile of the disease and emphasize the need for individualized comprehensive assessment of mental development in patients with merosinopathy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>мерозин-дефицитная мышечная дистрофия</kwd><kwd>ген LAMA2</kwd><kwd>белок ламинин-211</kwd><kwd>DP-3</kwd><kwd>нарушения развития</kwd><kwd>когнитивное развитие</kwd><kwd>нарушения коммуникации</kwd></kwd-group><kwd-group xml:lang="en"><kwd>merosin-deficient muscular dystrophy</kwd><kwd>LAMA2 gene</kwd><kwd>laminin-211 protein</kwd><kwd>DP-3</kwd><kwd>developmental disorders</kwd><kwd>cognitive development</kwd><kwd>communication disorders</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira J., Gruber A., Cardoso M., et al. LAMA2 gene mutation update: Toward a more comprehensive picture of the laminin-α2 variome and its related phenotypes. Hum Mutat. 2018; 39 (10): 1314–1337.</mixed-citation><mixed-citation xml:lang="en">Oliveira J, Gruber A, Cardoso M, et al. LAMA2 gene mutation update: Toward a more comprehensive picture of the laminin-α2 variome and its related phenotypes. Hum Mutat. 2018; 39 (10): 1314–1337.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bouman K., Groothuis J.T., Doorduin J., et al. Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study. BMC Neurol. 2021; 21 (1): 313. Published 2021 Aug 12.</mixed-citation><mixed-citation xml:lang="en">Bouman K, Groothuis JT, Doorduin J, et al. Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENONrelated myopathy in children and adults: protocol of the LAST STRONG study. BMC Neurol. 2021; 21 (1): 313. Published 2021 Aug 12.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Jones K.J. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. Journal of Medical Genetics. 2001. № 10 (38). C. 649–657.</mixed-citation><mixed-citation xml:lang="en">Jones KJ. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. Journal of Medical Genetics. 2001. № 10 (38). C. 649–657.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Løkken N., Born A.P., Duno M., Vissing J. LAMA2-related myopathy: Frequency among congenital and limb-girdle muscular dystrophies. Muscle Nerve. 2015; 52 (4): 547–553.</mixed-citation><mixed-citation xml:lang="en">Løkken N, Born AP, Duno M, Vissing J. LAMA2- related myopathy: Frequency among congenital and limb-girdle muscular dystrophies. Muscle Nerve. 2015; 52 (4): 547–553.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Camelo C.G., Artilheiro M.C., Martins Moreno C.A., et al. Brain MRI Abnormalities, Epilepsy and Intellectual Disability in LAMA2 Related Dystrophy – a Genotype/Phenotype Correlation. J Neuromuscul Dis. 2023; 10 (4): 483–492.</mixed-citation><mixed-citation xml:lang="en">Camelo CG, Artilheiro MC, Martins Moreno CA, et al. Brain MRI Abnormalities, Epilepsy and Intellectual Disability in LAMA2 Related Dystrophy – a Genotype/Phenotype Correlation. J Neuromuscul Dis. 2023; 10 (4): 483–492.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira J., Santos R., Soares-Silva I., et al. LAMA2 gene analysis in a cohort of 26 congenital muscular dystrophy patients. Clin Genet. 2008; 74 (6): 502–512.</mixed-citation><mixed-citation xml:lang="en">Oliveira J, Santos R, Soares-Silva I, et al. LAMA2 gene analysis in a cohort of 26 congenital muscular dystrophy patients. Clin Genet. 2008; 74 (6): 502–512.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tan D., Ge L., Fan Y., et al. Natural history and genetic study of LAMA2-related muscular dystrophy in a large Chinese cohort. Orphanet J Rare Dis. 2021; 16 (1): 319. Published 2021 Jul 19.</mixed-citation><mixed-citation xml:lang="en">Tan D, Ge L, Fan Y, et al. Natural history and genetic study of LAMA2-related muscular dystrophy in a large Chinese cohort. Orphanet J Rare Dis. 2021; 16 (1): 319. Published 2021 Jul 19.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zambon A.A., Ridout D., Main M., et al. LAMA2-related muscular dystrophy: Natural history of a large pediatric cohort. Ann Clin Transl Neurol. 2020; 7 (10): 1870–1882.</mixed-citation><mixed-citation xml:lang="en">Zambon AA, Ridout D, Main M, et al. LAMA2-related muscular dystrophy: Natural history of a large pediatric cohort. Ann Clin Transl Neurol. 2020; 7 (10): 1870–1882.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira J., Parente Freixo J., Santos M., Coelho T. LAMA2 Muscular Dystrophy. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; June 7, 2012.</mixed-citation><mixed-citation xml:lang="en">Oliveira J, Parente Freixo J, Santos M, Coelho T. LAMA2 Muscular Dystrophy. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; June 7, 2012.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Natera-de Benito D., Muchart J., Itzep D., et al. Epilepsy in LAMA2-related muscular dystrophy: An electro-clinico-radiological characterization. Epilepsia. 2020; 61 (5): 971–983.</mixed-citation><mixed-citation xml:lang="en">Natera-de Benito D, Muchart J, Itzep D, et al. Epilepsy in LAMA2-related muscular dystrophy: An electro-clinico-radiological characterization. Epilepsia. 2020; 61 (5): 971–983.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Huang X., Tan D., Zhang Z., et al. Unique genotypephenotype correlations within LAMA2-related limb girdle muscular dystrophy in Chinese patients. Front Neurol. 2023; (14): 1158094. Published 2023 May 3.</mixed-citation><mixed-citation xml:lang="en">Huang X, Tan D, Zhang Z, et al. Unique genotype-phenotype correlations within LAMA2-related limb girdle muscular dystrophy in Chinese patients. Front Neurol. 2023; (14): 1158094. Published 2023 May 3.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Salvati A., Bonaventura E., Sesso G., Pasquariello R., et al. Epilepsy in LAMA2-related muscular dystrophy: A systematic review of the literature. Seizure. 2021; (91): 425–436.</mixed-citation><mixed-citation xml:lang="en">Salvati A, Bonaventura E, Sesso G, Pasquariello R, et al. Epilepsy in LAMA2-related muscular dystrophy: A systematic review of the literature. Seizure. 2021; (91): 425–436.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Radner S., Banos C., Bachay G., et al. β2 and γ3 laminins are critical cortical basement membrane components: ablation of Lamb2 and Lamc3 genes disrupts cortical lamination and produces dysplasia. Dev Neurobiol. 2013; 73 (3): 209–229.</mixed-citation><mixed-citation xml:lang="en">Radner S, Banos C, Bachay G, et al. β2 and γ3 laminins are critical cortical basement membrane components: ablation of Lamb2 and Lamc3 genes disrupts cortical lamination and produces dysplasia. Dev Neurobiol. 2013; 73 (3): 209–229.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yurchenco P.D., McKee K.K., Reinhard J.R., Rüegg M.A. Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies. Matrix Biol. 2018; (71–72): 174–187.</mixed-citation><mixed-citation xml:lang="en">Yurchenco PD, McKee KK, Reinhard JR, Rüegg MA. Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies. Matrix Biol. 2018; (71–72): 174–187.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Alkan A., Sigirci A., Kutlu R., et al. Merosin-negative congenital muscular dystrophy: diffusion-weighted imaging findings of brain. Journal of Child Neurology. 2007. Vol. 22, № 5. P. 655–659.</mixed-citation><mixed-citation xml:lang="en">Alkan A, Sigirci A, Kutlu R, et al. Merosin-negative congenital muscular dystrophy: diffusion-weighted imaging findings of brain. Journal of Child Neurology. 2007; 22 (5): 655–659.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Arreguin A.J., Colognato H. Brain Dysfunction in LAMA2-Related Congenital Muscular Dystrophy: Lessons From Human Case Reports and Mouse Models. Frontiers in Molecular Neuroscience. 2020. Vol. 13. Р. 118.</mixed-citation><mixed-citation xml:lang="en">Arreguin AJ, Colognato H. Brain Dysfunction in LAMA2-Related Congenital Muscular Dystrophy: Lessons From Human Case Reports and Mouse Models. Frontiers in Molecular Neuroscience. 2020; (13): 118.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">De Laat E.C.M., Houwen-van Opstal S.L.S., Bouman K., et al. A 5-year natural history study in LAMA2- related muscular dystrophy and SELENON-related myopathy: the Extended LAST STRONG study. BMC Neurol. 2024; 24 (1): 409. Published 2024 Oct 23.</mixed-citation><mixed-citation xml:lang="en">De Laat ECM, Houwen-van Opstal SLS, Bouman K, et al. A 5-year natural history study in LAMA2-related muscular dystrophy and SELENON-related myopathy: the Extended LAST STRONG study. BMC Neurol. 2024; 24 (1): 409. Published 2024 Oct 23.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Enzmann C., Steiner L., Pospieszny K., et al. &amp; Swiss-Reg-NMD Group (2024) A Multicenter Cross-Sectional Study of the Swiss Cohort of LAMA2-Related Muscular Dystrophy. Journal of neuromuscular diseases. 19. Alpern G.D. Developmental profile 3 (3rd ed.). 2009.</mixed-citation><mixed-citation xml:lang="en">Enzmann C, Steiner L, Pospieszny K, et al. &amp; Swiss-Reg-NMD Group (2024) A Multicenter Cross-Sectional Study of the Swiss Cohort of LAMA2-Related Muscular Dystrophy. Journal of neuromuscular diseases.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнов И.И., Попова Е.С., Серебровская О.В. и соавт. Изучение возможности применения методик для оценки расстройств развития экспрессивной речи у детей 3–6 лет. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024. № 2 (124). C. 103–109.</mixed-citation><mixed-citation xml:lang="en">Alpern GD. Developmental profile 3 (3rd ed.). 2009.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Caravale B., Castronovo A., Narducci L., et al. Neurodevelopment in Preterm Children at 12 Months: Aligning Clinical Observations and Parental Insight. 2025. № 9 (12).</mixed-citation><mixed-citation xml:lang="en">Smirnov II, Popova ES, Serebrovskaya OV, et al. Studying the possibility of using methods for assessing expressive speech developmental disorders in children 3–6 years old. S.S. Korsakov Journal of Neurology and Psychiatry. 2024; 124 (11 vyp 2): 103–109 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yeleswarapu SP W.C., Chan Y.H., et al Outcomes from an enhanced developmental screening programme in Singapore 2025. (202:106220).</mixed-citation><mixed-citation xml:lang="en">Caravale B, Castronovo A, Narducci L, et al. Neurodevelopment in Preterm Children at 12 Months: Aligning Clinical Observations and Parental Insight. 2025. № 9 (12).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Папина Ю.О., Заваденко Н.Н., Мельник Е.А и соавт. Оценка социально-эмоционального, когнитивного, коммуникативного развития и адаптивного поведения детей со спинальной мышечной атрофией 5q. Нервно-мышечные болезни. № 1 (15). C. 39–52.</mixed-citation><mixed-citation xml:lang="en">Yeleswarapu SP WC, Chan YH, et al Outcomes from an enhanced developmental screening programme in Singapore 2025. (202:106220).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Borella L.F.M., Pereira F.V., Mimura P.M.P., et al. Widening the spectrum of LAMA 2 congenital muscular dystrophy (MDC1A): cobblestone malformation. Arq Neuropsiquiatr. 2022; 80 (3): 333–334.</mixed-citation><mixed-citation xml:lang="en">Papina YuO, Zavadenko NN, Melnik EA, et al. Assessment of social-emotional, cognitive, communicative development and adaptive behavior in children with spinal muscular atrophy 5q. Nervno‑myshechnye bolezni = Neuromuscular Diseases. 2025; 15 (1): 39–52 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Jayakody H., Zarei S., Nguyen H., et al. Cobblestone Malformation in LAMA2 Congenital Muscular Dystrophy (MDC1A). J Neuropathol Exp Neurol. 2020; 79 (9): 998–1010.</mixed-citation><mixed-citation xml:lang="en">Borella LFM, Pereira FV, Mimura PMP, et al. Widening the spectrum of LAMA 2 congenital muscular dystrophy (MDC1A): cobblestone malformation. Arq Neuropsiquiatr. 2022; 80 (3): 333–334.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Vigliano P., Dassi P., Di Blasi C., et al. LAMA2 stop-codon mutation: merosin-deficient congenital muscular dystrophy with occipital polymicrogyria, epilepsy and psychomotor regression. Eur J Paediatr Neurol. 2009; 13 (1): 72–76.</mixed-citation><mixed-citation xml:lang="en">Jayakody H, Zarei S, Nguyen H, et al. Cobblestone Malformation in LAMA2 Congenital Muscular Dystrophy (MDC1A). J Neuropathol Exp Neurol. 2020; 79 (9): 998–1010.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed M., Marziali L.N., Arenas E., et al. French- Constant C. Laminin α2 controls mouse and human stem cell behaviour during midbrain dopaminergic neuron development. 2019. № 16 (146).</mixed-citation><mixed-citation xml:lang="en">Vigliano P, Dassi P, Di Blasi C, et al. LAMA2 stop-codon mutation: merosin-deficient congenital muscular dystrophy with occipital polymicrogyria, epilepsy and psychomotor regression. Eur J Paediatr Neurol. 2009; 13 (1): 72–76.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Morales M., Margolis E.B. Ventral tegmental area: cellular heterogeneity, connectivity and behavior. № 2 (18). P. 73–85.</mixed-citation><mixed-citation xml:lang="en">Ahmed M, Marziali LN, Arenas E, et al. French-Constant C. Laminin α2 controls mouse and human stem cell behaviour during midbrain dopaminergic neuron development. 2019. № 16 (146).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Zha J., Yu Y., Cao F., et al. LAMA2 variants associated with muscular dystrophy, brain structural abnormalities, and epilepsy: a genotype-phenotype study. Front Neurol. 2026; (16): 1728652. Published 2026 Jan 6.</mixed-citation><mixed-citation xml:lang="en">Morales M, Margolis EB. Ventral tegmental area: cellular heterogeneity, connectivity and behavior. № 2 (18). P. 73–85.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ding M., Wang X., Zeng Y., et al. Missense mutations in LAMA2 causing a new phenotype of mild cognitive impairment, proximal myopathy, seizure, and severe leukoencephalopathy: A case report and protein analysis. Clin Neuropathol. 2019; 38 (3): 100–108.</mixed-citation><mixed-citation xml:lang="en">Zha J, Yu Y, Cao F, et al. LAMA2 variants associated with muscular dystrophy, brain structural abnormalities, and epilepsy: a genotype-phenotype study. Front Neurol. 2026; (16): 1728652. Published 2026 Jan 6.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ding M, Wang X, Zeng Y, et al. Missense mutations in LAMA2 causing a new phenotype of mild cognitive impairment, proximal myopathy, seizure, and severe leukoencephalopathy: A case report and protein analysis. Clin Neuropathol. 2019; 38 (3): 100–108.</mixed-citation><mixed-citation xml:lang="en">Ding M, Wang X, Zeng Y, et al. Missense mutations in LAMA2 causing a new phenotype of mild cognitive impairment, proximal myopathy, seizure, and severe leukoencephalopathy: A case report and protein analysis. Clin Neuropathol. 2019; 38 (3): 100–108.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
